Astra Pharmaceuticals AB
Astra Pharmaceuticals AB, a prominent player in the pharmaceutical industry, is headquartered in Sweden (SE) and operates extensively across Europe and beyond. Founded in the early 2000s, the company has established itself as a leader in developing innovative therapies, particularly in the fields of oncology and neurology. Astra Pharmaceuticals is renowned for its commitment to research and development, focusing on unique drug formulations that address unmet medical needs. Their core products include advanced biologics and targeted therapies, which distinguish them in a competitive market. With a strong emphasis on quality and efficacy, Astra Pharmaceuticals has achieved significant milestones, including several successful product launches and collaborations with leading research institutions. Recognised for its contributions to healthcare, Astra Pharmaceuticals AB continues to strengthen its market position, driven by a passion for improving patient outcomes and advancing medical science.
DitchCarbon Score
How does Astra Pharmaceuticals AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astra Pharmaceuticals AB's score of 78 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astra Pharmaceuticals AB, headquartered in Sweden (SE), currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family relationship with AstraZeneca PLC, from which it inherits climate commitments and initiatives. AstraZeneca PLC has established significant climate targets, including commitments to reduce greenhouse gas emissions across its operations. These targets are cascaded down to Astra Pharmaceuticals AB, reflecting the parent company's dedication to sustainability. AstraZeneca has set science-based targets (SBTi) and participates in various initiatives such as the Carbon Disclosure Project (CDP) and RE100, aiming for 100% renewable energy usage. While Astra Pharmaceuticals AB does not have its own emissions data or specific reduction targets, it aligns with AstraZeneca's broader climate strategy, which focuses on reducing Scope 1, 2, and 3 emissions. The commitment to sustainability and climate action is integral to the company's operational ethos, ensuring that it contributes to global efforts in combating climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astra Pharmaceuticals AB is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
